Systemic psoriasis treatment may resolve subclinical enthesitisMay 1, 2015Psoriatic ArthritisSpondyloarthropathies
New tool aims to improve monitoring of psoriatic arthritisMay 1, 2015Psoriatic ArthritisSpondyloarthropathies
Older psoriasis patients experience more adverse eventsApril 29, 2015SpondyloarthropathiesPsoriatic Arthritis
New psoriatic arthritis screening tool passes initial validationApril 17, 2015Psoriatic ArthritisSpondyloarthropathies
Psoriatic arthritis associated with heavy drinkingApril 17, 2015Psoriatic ArthritisSpondyloarthropathies
Apremilast meets psoriasis endpoints at week 32April 12, 2015SpondyloarthropathiesPsoriatic Arthritis
Ixekizumab met psoriasis endpoints by week 12, with durable response at 60 weeksApril 9, 2015Psoriatic ArthritisSpondyloarthropathies
IL-23 inhibitor topped ustekinumab against psoriasisApril 2, 2015Psoriatic ArthritisSpondyloarthropathies
Traditional risk factors raise cardiovascular risk in PsAApril 2, 2015SpondyloarthropathiesPsoriatic Arthritis
No increased risk of lung disease with methotrexateApril 2, 2015Psoriatic ArthritisSpondyloarthropathies
Rheumatologists support biosimilars, with caveatsApril 1, 2015Ankylosing spondylitisPsoriatic ArthritisSpondyloarthropathiesRheumatoid ArthritisBusiness of Medicine
Methotrexate and biologics linked to higher zoster risk in psoriasisMarch 22, 2015Psoriatic ArthritisSpondyloarthropathies
Secukinumab beat ustekinumab for psoriasis, with difference by week fourMarch 21, 2015SpondyloarthropathiesPsoriatic Arthritis
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeksMarch 21, 2015SpondyloarthropathiesPsoriatic Arthritis
